Glenmark rises on receiving USFDA approval for generic version of Solaraze Gel

14 Sep 2016 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs 880.45, up by 5.35 points or 0.61% from its previous closing of Rs 875.10 on the BSE.

The scrip opened at Rs. 876.00 and has touched a high and low of Rs. 891.00 and Rs. 876.00 respectively. So far 19712 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1074.90 on 06-Oct-2015 and a 52 week low of Rs. 671.50 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 915.00 and Rs. 834.50 respectively. The current market cap of the company is Rs. 24799.76 crore.

The promoters holding in the company stood at 46.48%, while Institutions and Non-Institutions held 42.06% and 11.46% respectively.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Diclofenac Sodium Gel, 3%, the generic version of Solaraze Gel, 3% of Fougera Pharmaceuticals Inc.

The Solaraze Gel, 3% market had achieved annual sales of approximately $297.9 million, according to IMS Health sales data for the twelve month period ending July 2016.

Glenmark’s current portfolio consists of 110 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

 

Glenmark Pharma Share Price

1954.80 7.20 (0.37%)
18-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.35
Dr. Reddys Lab 1279.60
Cipla 1499.10
Zydus Lifesciences 913.85
Lupin 2118.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×